ArticleDigestive diseases and sciences2026
Multi-center Study of the Association Between Serum Lipid Levels and Recurrent Common Bile Duct Stone After Endoscopic Retrograde Cholangiopancreatography with Propensity Score Matching Analysis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bugging In: Rethinking Colorectal Cancer Pathogenesis Through the Gut-Tumor-Microbiota Axis.Digestive diseases and sciences · 2026Article
- Knives Out-Rethinking the Learning Curve of Esophageal ESD.Digestive diseases and sciences · 2026Article
- The Acid Test - Does Ketoacidosis Affect the Course and Prognosis of Hypertriglyceridemic Acute Pancreatitis?Digestive diseases and sciences · 2026Article
- Optimizing Risk Stratification in HTG-AP and DKA: The Case for Broader Biomarker Inclusion.Digestive diseases and sciences · 2026Article
- Decoding FZD6 in Biliary Atresia: A Target Without a Trail.Digestive diseases and sciences · 2026Article
- Case Report: Clip migration induced recurrent choledocholithiasis after laparoscopic common bile duct exploration.Frontiers in medicine · 2026Article
- Comments on "Clinical Characteristics and Outcomes of Hypertriglyceridemic Acute Pancreatitis Concomitant with Diabetic Ketoacidosis".Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent common bile duct (CBD) stones after endoscopic retrograde cholangiopancreatography (ERCP) is a significant clinical issue. While the association between serum lipid levels and gallstones has been established, its impact on recurrent CBD stone is less clear. This study aims to investigate the association between serum lipid levels and recurrent CBD stone, further subclassified into different subgroups. We also try to explore effective drugs to decrease the occurrence of recurrent CBD stone. MATERIALS AND
methodsThis multi-institutional study acquired patients' data from Chang Gung Memorial Hospitals using Chang Gung Research Database (CGRD) from 2002/1/1 to 2020/12/31. We analyzed the association between metabolic risk factors and recurrent CBD stone after ERCP using propensity score matching and then subclassified these patients into cholecystectomy, cirrhosis, and hyperlipidemia. Additionally, medications aimed at controlling serum lipid levels were investigated for their potential to reduce the recurrence rate of CBD stones.
resultsTotally, 5132 patients were enrolled. Our results showed that higher cholesterol level and HbA1C above 6.5% are risk factors of CBD stone recurrence after ERCP when using propensity score matching. However, triglyceride (TG) and high-density lipoprotein (HDL) were presented as protective factors. These metabolic factors may be variable in different subgroups. Additionally, statin and aspirin might be effective drugs to reduce CBD stone recurrence rate.
conclusionsSerum lipid level and HbA1C were found to be associated with recurrent CBD stone after ERCP but variable in different subgroups. Statin and aspirin might reduce the risk of CBD stone recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.